CDTX Cidara Therapeutics, Inc. Insider Trading

Cidara CEO Jeffrey Stein purchased 4,262 shares across 4 separate transactions (2017–2020) for $339,039.60; post-trade holdings 2,379 shares despite negative net income of $-83,233,000.00.

Jeffrey Stein, President & CEO of Cidara Therapeutics, made 4 separate open-market purchases totaling 4,262 shares for $339,039.60 with a blended average price of $79.55, accumulating to 2,379 shares post-transaction. The purchases spanned from March 2017 through November 2020, with the most recent buy at $40.01 per share in November 2020 when the stock was trading significantly below earlier acquisition prices. The company reported zero latest-quarter revenue and annual net income of $-83,233,000.00, with annual revenue declining 98.0% year-over-year, indicating severe operational distress. At his prior two same-ticker purchases (June 2024 and August 2023), only one showed a positive 90-day outcome, and his cross-ticker track record across 2 prior buys averaged +779.0% 90-day return but reflects limited transaction history. The current price of $221.38 is near the 52-week high, suggesting material appreciation since the earlier tranches despite the company's deteriorating fundamentals.

COO Shane Ward sells 9,959 shares of CDTX at $220.08 ($2.2M); stock near 52-week high after +106% in 30 days

Ward Shane, serving as COO & CLO, sold 9,959 shares at $220.08, reducing holdings by -28.5% from 35.0K to 25.0K shares. The transaction occurred when CDTX was -0.2% from its 52-week high of $220.98 and after a 30-day rally of +106.0% and 90-day surge of +236.2%. Despite the sharp stock appreciation, the company reported $0.00 quarterly revenue and net income of $-83.2M, with annual revenue declining -98.0% year-over-year and negative full-year profitability. The sale of a significant portion of executive holdings during peak valuation and exceptional near-term price appreciation, coupled with the company's deteriorating financial position, presents a notable divergence between equity-holder actions and the stock's recent momentum.

RA Capital buys 2,272,727 shares of Cidara at $44.00; position grows 208.0%; stock up 124.7% in 30 days

RA Capital Management purchased 2,272,727 shares at $44.00 for $99,999,988.00, increasing its stake by 208.0% to 3,365,523 shares post-transaction. The $100.0M acquisition represents a substantial director commitment in a company currently unprofitable with revenue of $0.00 in the latest quarter and annual revenue declining 98.0% year-over-year. The timing follows sharp momentum: Cidara stock has risen 124.7% over 30 days and 157.4% over 90 days, trading within 1.5% of its 52-week high of $49.45. Against RA Capital's cross-ticker track record showing 20 prior buys with a 60.00% 90-day win rate and +1.0% average 90-day return, the purchase of this distressed biotech at recent peaks deserves scrutiny given the company's revenue collapse and persistent unprofitability.

Director Mineo Chrysa buys 3,320 shares at blended avg $22.26 in 2-transaction filing at loss-making biotech.

Mineo Chrysa, a Director at Cidara Therapeutics, made 2 separate purchases totaling 3,320 shares for $73,895.57, acquired at $21.71 on 2025-06-02 and $23.44 on 2025-06-03. This represents a new position; Chrysa held zero shares prior to these transactions. The purchases occurred while CDTX stock was near its 52-week high of $27.30 and has since appreciated 11.9% in the 30-day period following the transaction window, trading at $24.05 currently (down 11.9% from the 52-week high). Cidara's fundamentals remain challenged: the company reported $0.00 revenue in the latest quarter, a net loss of $-23,480,000.00, and annual revenue contraction of -98.0%, reflecting an unprofitable biotech in a critical phase. A director's initial equity stake purchase warrants baseline disclosure attention, though the absence of prior holdings history and the company's severe loss position limit the interpretive signal.